Junovan™ (Mepact™, muramyltripeptide phosphatidylethanolamine or mifamurtide) is IDM Pharma’s lead product candidate. It is a fully synthetic chemical entity with a bacterial cell wall component designed to activate macrophages in vivo, thereby increasing their capacity to destroy cancer cells.